Paris, May 12, 2010 (ots/PRNewswire) – Sanofi-aventis announced today the initiation of a multinational, randomized, double-blind Phase IIIb trial, PALLAS, to assess the potential clinical benefit of Multaq(R) (dronedarone) in over 10,000 patients with permanent atrial fibrillation (AF) to reduce major adverse cardiovascular events. The announcement was made during Heart Rhythm 2010, the Heart Rhythm [...]
Tag Archive > Cardiovascular Outcomes
Sanofi-aventis Launches Major New Registry Including Over 10,000 Patients Worldwide With Atrial Fibrillation
Paris, November 16 (ots/PRNewswire) – – The RealiseAF Registry Will Help to Better Define and Understand the Cardiovascular Risk Profile of AF Patients and Characterize Their Cardiovascular Outcomes Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today the launch of the RealiseAF registry (Real Life global Survey Evaluating patients with Atrial Fibrillation), an international, cross-sectional, observational [...]
In Heart Failure Patients Treated With ACE Inhibitor and/or Beta Blocker, Higher Plasma Renin Activity is Related to Greater Risk of Mortality
Basel, Switzerland (ots/PRNewswire) – – New Analysis of Data From landmark ‘Valsartan Heart Failure Trial’ Adds to Growing Evidence That Plasma Renin Activity (PRA) is Linked to Cardiovascular Outcomes (1-3) – PRA is a Measure of the Activity of the Renin Angiotensin System (RAS) – The Only High Blood Pressure Treatment That Blocks the RAS [...]
